



# Intrasense and the ICM sign a partnership to optimize a new solution dedicated to oncology

Montpellier, France, February 6, 2023, 5:45 pm CET

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine.

## New oncology platform in prototype phase

As part of the development of its new software platform dedicated to oncology patient care, Intrasense has approached the Montpellier Regional Cancer Institute. The medical teams of the ICM were asked to evaluate the prototype and the first versions of the solution with the ambition to use it in their daily practice.

The new platform is designed to streamline and simplify the care process related to medical imaging in oncology. It will provide oncology professionals with a full range of clinical, collaborative and research tools, perfectly addressing all aspects of patient management.

Initial evaluations of the prototype by the ICM teams have highlighted the need for an intelligent user interface and tools that are perfectly adapted to the expectations of radiologists in oncology practice. Further tests will be carried out throughout the year with a view to marketing a software platform enhanced with innovative functionalities in early 2024.

*"The medical image is crucial in oncology. As soon as a diagnosis is made, a race against the clock begins; gaining fluidity and quality in the patient's care workflow allows us to optimize patient care,"* explains **Professor Marc Ychou, General Manager of the ICM**. *Intrasense's teams are offering a concrete and innovative solution that will optimize and facilitate the daily work of our multidisciplinary teams.*



## The ICM, a key player in the fight against cancer in France

The Montpellier Regional Cancer Institute is part of the network of 18 cancer centers (CLCC) of the Unicancer network, which has built a model for comprehensive and innovative cancer care in France. The establishment centralizes all treatments dedicated to cancer and brings together multidisciplinary teams of more than 1,000 employees, who work in a coordinated manner with patients throughout their care.

Recognized at the national level for its expertise and innovation in the care of cancer patients, the MHI is also part of a European network, as an active member of the Organization of European Cancer Institutes (OECI), which brings together the largest cancer research centers. This distinction is a strong recognition of its expertise in cancer care, research and training. The MHI also has recognized skills in radiology and in international evaluation criteria, expertise confirmed by the implementation of an automated solution in-house.

The ICM is also fully anchored in the ecosystem federated by MedVallée, whose objective is to make the Montpellier metropolitan area a leading research and innovation area, with an entrepreneurial dynamic, anchored in health and focused on the medicine of the future.

*"We are very proud to collaborate with the ICM, a key player in cancer treatment and research in France. This partnership is a major milestone; it confirms that the value proposition driven by our new solution perfectly meets the expectations of physicians and clinical research actors,"* said **Nicolas Reymond, Intrasense CEO.**

## A key step before commercialization

This collaboration with the ICM is part of Intrasense's development of its solution dedicated to oncology. This first step of validation of the functional prototype prepares the industrialization of an optimal solution, and the marketing of the product line in early 2024.

Natively integrating artificial intelligence and collaborative tools dedicated to routine and clinical research, this innovative solution offers significant advantages to improve the accuracy and efficiency of diagnosis as well as multidisciplinary collaboration in oncology.

The strong interest expressed by healthcare professionals, future users of the solution, particularly during the Journées Francophones de Radiologie (JFR) last October, demonstrates the innovative and highly anticipated nature of this new platform dedicated to oncology. Other partnerships with complementary oncology players in France and Europe are currently being concluded and will enable the testing and adoption of the first commercialized versions of the solution.



## About Intrasense

**Founded in 2004, Intrasense develops and markets a unique medical device, Myrian®, a software platform that facilitates and secures diagnosis, decision making and therapeutic follow-up.**

Thanks to Myrian®, more than 1,000 healthcare institutions over 40 countries benefit from a single, integrated platform for reading all types of images (MRI, CT, etc.). Enriched with expert clinical applications for specific pathologies, Myrian® offers a universal medical image processing solution that can be integrated into all

healthcare information systems. Intrasense has 55 employees, including 20 dedicated to Research and Development. Labelled as an "innovative company" by the BPI, it has invested more than 12 million euros in Research and Development since its creation.

More information on [www.intrasense.fr](http://www.intrasense.fr).

## About the ICM

**Created in 1923, the Regional Cancer Institute of Montpellier is one of the 18 Centers for the Fight against Cancer (CLCC) that make up the Federation UNICANCER.**

The MHI is a private health institution of collective interest (ESPIC), providing a public hospital service and recognized as being of public utility. It is the regional reference center of excellence in cancer research and in the care of cancer patients. The ICM's ambition is to

offer each patient a personalized treatment best suited to his or her situation, using specialized medicine based on in-depth, multidisciplinary knowledge of cancers and the expertise of its professionals.

Learn more at [www.icm.unicancer.fr](http://www.icm.unicancer.fr).

### Intrasense

Salomé Sylvestre  
Communications Officer

Phone: +334 67 13 01 30  
[investisseurs@intrasense.fr](mailto:investisseurs@intrasense.fr)

### ICM

Ivannick Chataigne  
Communication Director

Phone: +334 67 61 45 15  
[Ivannick.Chataigne@icm.unicancer.fr](mailto:Ivannick.Chataigne@icm.unicancer.fr)

### NewCap

Thomas Grojean  
Financial Communication and IR

Phone: +331 44 71 20 40  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)